Deanol in the management of involuntary movement disorders: a review.
D000109:Acetylcholine / Q000378:metabolism; D003642:Deanol / Q000008:administration & dosage / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000378:metabolism; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D007980:Levodopa / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008959:Models, Neurological; D009069:Movement Disorders / Q000188:drug therapy*; D010300:Parkinson Disease / Q000188:drug therapy; D010830:Physostigmine / Q000627:therapeutic use; D012107:Research Design; D013997:Time Factors
D004983:Ethanolamines; D003642:Deanol; D007980:Levodopa; D010830:Physostigmine; D000109:Acetylcholine; D004298:Dopamine